(Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA ... Information identifying such important factors is contained under ...
Renovaro previously received a notification letter from the Nasdaq Listing Qualifications Department on September 12, 2024, notifying the Company that, over the previous 30 consecutive business days, ...